|
|
|
|
| LEADER |
01328nam a2200253 u 4500 |
| 001 |
EB002010808 |
| 003 |
EBX01000000000000001173707 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 100 |
1 |
|
|a Brett, Kendra
|
| 245 |
0 |
0 |
|a Direct observational therapy for the treatment of tuberculosis
|h Elektronische Ressource
|b review of clinical evidence and guidelines
|c Kendra Brett, Melissa Severn
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, November 24, 2020
|
| 300 |
|
|
|a 1 PDF file (51 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Severn, Melissa
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567074
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of the current report is to summarize and critically appraise the relevant evidence regarding the provision of DOT for the treatment of TB. Additionally, evidence-based guidelines with recommendations regarding the use of DOT for the treatment of TB will be reviewed
|